Mayne Pharma Group Ltd insider trades: HedgePath Pharmaceuticals (HPPI) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mayne Pharma Group Ltd reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2017 | HPPI | ↑ Buy | 600,000 | $162660.00 | $97.60B | Direct | Feb 12, 2018 (55d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mayne Pharma Group Ltd's insider trades
Mayne Pharma Group Ltd is a 10% owner of HedgePath Pharmaceuticals (HPPI). Since Dec 19, 2017, it has reported 1 open-market purchase worth $97.60B and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include other transactions (6 filings), option exercises (2 filings), grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HPPI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.